Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Attention deficit hyperactivity disorder: an update.

Alexander K C Leung1, Jean François Lemay

  • 1Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.

Advances in Therapy
|April 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression and Correlation Analysis of Neuropeptide Family Members in the Peripheral Blood of Patients with COVID-19.

Current pediatric reviews·2026
Same author

A Narrative Review of Dietary Interventions and Supplementation for the Prevention and Treatment of Atopic Dermatitis.

Current pediatric reviews·2026
Same author

Correction: The future of severe acute respiratory syndrome-coronavirus and coronavirus disease.

World journal of pediatrics : WJP·2026
Same author

Infectious associations in childhood Kawasaki Disease.

Current pediatric reviews·2026
Same author

The EAT Algorithm: A Visual Tool to De-escalate Food Avoidance Anxiety in Parents.

Current pediatric reviews·2026
Same author

The future of severe acute respiratory syndrome-cornavirus and coronavirus disease.

World journal of pediatrics : WJP·2026
Same journal

Correction: Low-Dose Naltrexone: What is the Evidence? A Narrative Review.

Advances in therapy·2026
Same journal

Usability and Acceptance of Autoinjector and Prefilled Syringe Devices by Patients with Generalized Myasthenia Gravis in a Human Factors Study.

Advances in therapy·2026
Same journal

Treatment Patterns and Decision Drivers in Chinese Patients with Locally Advanced Cervical Cancer: Results from a National Physician Survey.

Advances in therapy·2026
Same journal

Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.

Advances in therapy·2026
Same journal

Sacral Neuromodulation for Refractory Overactive Bladder: Closing the Gaps in Anatomy, Mechanisms, and Parameter Selection.

Advances in therapy·2026
Same journal

Exploring the Impact of Delivering Allergy Medication as Self-Care on Healthcare Greenhouse Gas Emissions in the United Kingdom.

Advances in therapy·2026
See all related articles

Attention deficit hyperactivity disorder (ADHD), a common neurobehavioral disorder in children, often requires stimulant medication. New delivery systems now offer convenient once-daily dosing options for managing ADHD symptoms effectively.

Area of Science:

  • Neurobehavioral disorders
  • Pediatric neurology
  • Pharmacology

Background:

  • Attention deficit hyperactivity disorder (ADHD) is the most prevalent neurobehavioral disorder in school-aged children, affecting 3-5% of this population.
  • The combined subtype of ADHD is the most frequent presentation, comprising 50-70% of all diagnosed cases.
  • Stimulant medication is the primary treatment, but short-acting formulations can pose challenges for consistent symptom management.

Purpose of the Study:

  • To highlight the challenges associated with short-acting stimulant medications for ADHD.
  • To introduce recent technological advancements in drug delivery systems for ADHD treatment.
  • To present once-daily dosing as a viable and improved option for ADHD management.

Main Methods:

Related Experiment Videos

  • Review of current ADHD treatment paradigms.
  • Analysis of technological innovations in pharmaceutical delivery.
  • Evaluation of once-daily dosing strategies for stimulant medications.

    • Main Results:

    • Short-acting stimulant medications have limitations in providing sustained symptom control.
    • Advanced delivery systems have enabled the development of once-daily stimulant formulations.
    • These new formulations offer a more convenient and potentially more effective treatment option for many patients.

    Conclusions:

    • Technological advancements in delivery systems are improving ADHD management.
    • Once-daily dosing of stimulant medication represents a significant benefit for patients with ADHD.
    • This approach addresses the limitations of short-acting formulations, enhancing treatment adherence and efficacy.